Jaewon Ryu
TELEFLEXAbout Jaewon Ryu
Jaewon Ryu, M.D., 51, has served as an independent director of Teleflex since 2023 and sits on the Compensation Committee. He is currently CEO of Risant Health (since April 2024) and previously served as President & CEO of Geisinger Health (2019–2024); his background spans care delivery, health plan operations, corporate healthcare law, and policy roles at CMS and the VA, providing deep expertise in care delivery, payment, and regulatory oversight .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Risant Health | Chief Executive Officer | Apr 2024–present | Leads a nonprofit support organization to constituent health systems; IT/security oversight experience cited . |
| Geisinger Health | President & Chief Executive Officer; Interim President & CEO; EVP & Chief Medical Officer | Jun 2019–Apr 2024; Dec 2018–Jun 2019; Oct 2016–Dec 2018 | Led integrated system spanning clinical enterprise, health plan, med school, and research; strategy execution and operations . |
| Humana, Inc. | President, Integrated Care Delivery | Jan 2014–Sep 2016 | Value-based care delivery; payer-provider integration . |
| University of Illinois Hospital and Health Sciences System; Kaiser Permanente | Leadership roles | Not disclosed | Care delivery operations and leadership experience . |
| CMS; Department of Veterans Affairs | Government roles | Not disclosed | Health policy and regulatory experience . |
| Corporate healthcare attorney | Attorney | Not disclosed | Legal/regulatory expertise . |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Privia Health Group, Inc. | Director | Current | Public company board; no committee roles disclosed . |
Board Governance
- Independence: Board determined Dr. Ryu is independent under NYSE standards; reviewed Teleflex product sales to hospital systems affiliated with Risant Health and deemed them de minimis with no direct/indirect involvement by Ryu .
- Committee assignment: Compensation Committee member; the committee held six meetings in 2024; chair is Stuart Randle .
- Board activity: Board held six meetings in 2024; each director attended at least 75% of Board and committee meetings; all directors attended the 2024 annual meeting .
- Governance practices: Lead Independent Director structure; executive sessions at every regular meeting; prohibitions on hedging/pledging by directors; clawback policy compliant with Dodd-Frank/NYSE for executive incentive compensation .
Fixed Compensation
| Component | 2024 Program Terms | Dr. Ryu 2024 Cash Earned |
|---|---|---|
| Annual cash retainer | $67,000 | $85,000 (incl. retainer and meeting fees) . |
| Meeting fees | Board in person $2,000; Board phone $1,000; Committee $1,000 per meeting | Included in $85,000 . |
| Committee chair fees | Audit $22,500; Compensation $17,500; N&G $14,000 | Not applicable (not a chair) . |
Performance Compensation
| Instrument | Grant details (May 2024 unless noted) | Vesting | Dr. Ryu 2024 Grant Value/Count |
|---|---|---|---|
| Restricted Stock Units (RSUs) | Annual grant to non-management directors; 649 RSUs at grant-date fair value $200.48 per unit | Vests one year after grant; settlement in shares | $130,112; 649 RSUs . |
| Stock Options | Annual grant to non-management directors; 1,349 options at grant-date fair value $63.33 per share | Vests one year after grant; exercise price = closing price on grant date | $85,432; 1,349 options . |
| Equity mix | Director equity = RSUs ($137,000 program target) + Options ($90,000 program target) | — | Program structure detail . |
Performance metrics for director equity are time- and market-based (options require stock appreciation); no director PSUs disclosed .
Other Directorships & Interlocks
| Entity | Relationship | Relevance/Conflict Assessment |
|---|---|---|
| Risant Health (employer) | CEO; Teleflex sells products to hospital systems affiliated with Risant Health | Board concluded sales were de minimis relative to each party’s annual sales; Ryu had no direct/indirect involvement; independence not impaired . |
| Privia Health Group, Inc. | Director | No Teleflex-related transactions disclosed; no committee roles disclosed . |
Expertise & Qualifications
- Care delivery and payment expertise with operational leadership across integrated health systems and payer-provider models .
- Legal and regulatory background in corporate healthcare law and government policy (CMS, VA) .
- Information technology and security oversight experience from healthcare systems leadership .
Equity Ownership
| Metric | Value | Notes |
|---|---|---|
| Total beneficial ownership (Feb 1, 2025) | 2,679 shares | Includes options exercisable within 60 days . |
| Options exercisable within 60 days | 2,152 shares | Included in beneficial ownership . |
| Total options held (vested + unvested) as of Dec 31, 2024 | 3,501 shares | Director-level options outstanding . |
| Shares outstanding (Feb 1, 2025) | 46,279,820 | Company-wide . |
| Ownership as % of shares outstanding | ~0.0058% | Derived from 2,679 / 46,279,820 . |
| Director stock ownership guideline | 5x annual cash retainer (= $335,000) | RSUs count; options excluded . |
| Guideline compliance status (as of Dec 31, 2024) | Not yet met | Newer director; guideline applies with restriction on selling until met . |
Governance Assessment
- Independence affirmed despite potential interlock: Board reviewed Teleflex sales to Risant-affiliated hospital systems and deemed de minimis; independence maintained—a positive governance signal mitigating conflict concerns .
- Committee contribution: As a Compensation Committee member, Ryu participates in overseeing executive pay structures, including use of independent consultant FW Cook; committee met six times in 2024—supports oversight depth .
- Attendance: Met ≥75% threshold across Board/committee meetings and attended the 2024 annual meeting; acceptable engagement level; track for continued performance given CEO responsibilities at Risant .
- Alignment and incentives: Director pay mix includes options (requiring stock price appreciation) and RSUs; equity grants are annual and vest in one year, fostering near-term alignment but less performance-conditioned than PSUs; no director-specific clawbacks disclosed, though company maintains executive clawback policy .
- Ownership guideline gap: As of year-end 2024, Ryu had not yet met the 5x retainer stock ownership guideline; directors may not sell award shares until compliant—monitor for progress to strengthen alignment; new-director timing is a mitigating factor .
- Risk controls: Company prohibits director hedging/pledging—reduces misalignment risks; strong governance architecture (Lead Director, executive sessions, majority voting, proxy access) enhances board effectiveness .